IONS
IONIS PHARMACEUTICALS INC
$73.28
-0.73%
$12.1B
No data for this timeframe.
Vol
Market Cap$12.1B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders50 funds
Inst. Value$9.2B
Inst. Activity26 buys / 24 sells
Insider Activity0B / 20S
Insider Net $-$29.9M
SEC Reports7
Recent Activity
Oct 26, 2026
fda_pdufa
PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indicati
Jun 12, 2026
SEC
Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for severe hypertriglycerid
8-K — Impact 3/10
Jun 8, 2026
SEC
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 2026, and reported sha
8-K — Impact 3/10
Jun 4, 2026
Insider
HANTSON LUDWIG was granted 10,753 shares
Director
Jun 4, 2026
Insider
Reikes Peter N was granted 10,753 shares
Director
Jun 1, 2026
Insider
BERTHELSEN SPENCER R sold 8,000 shares
Director @ $75.67 ($605.4K)
May 28, 2026
SEC
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a 19% functional cure
8-K — Impact 7/10
Inst.
Artisan Partners Limited Partnership — ADD
2,058,308 shares ($154.6M)
Price Targets
$102.17
+39.4% upside
Strong Buy
Current $73.28
Low $47.00
Median $105.00
High $130.00
24 analysts
$47.00
$130.00
Analyst Ratings
10Strong Buy
17Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 19, 2026 | Citigroup | INITIATE | Buy |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 30, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.87 | $-1.03 — $-0.64 | -203% YoY | 7 |
| Next Q | $-0.81 | $-0.93 — $-0.61 | -32% YoY | 7 |
| Current FY | $-2.61 ▼ -2.1% | $-2.79 — $-2.04 | -69% YoY | 8 |
| Next FY | $-0.64 ▼ -2.4% | $-2.21 — $0.26 | 76% YoY | 9 |
Latest Reports
NEUTRAL
8-K
3/10
Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for severe hypertriglycerid
Jun 12, 2026
NEUTRAL
8-K
3/10
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 2026, and reported sha
Jun 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $1.8B | — |
| Capital World Investors | $1.6B | — |
| BlackRock, Inc. | $784.1M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $586.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | HANTSON LUDWIG | A | $0.00 |
| Jun 4, 2026 | Reikes Peter | A | $0.00 |
| Jun 1, 2026 | BERTHELSEN SPENCER | SELL | $605.4K |
| Jun 1, 2026 | BERTHELSEN SPENCER | M | $195.4K |
| May 14, 2026 | Monia Brett | M | $105.0K |
50 institutional holders with $9.2B total value (123,014,209 shares) as of 2026-Q1. Top holders: NOMURA, FMR, Capital. Net buying activity: 26 institutions added/increased vs 24 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 24,556,637 | $1.8B | 20.0% | — |
| 3 | Capital World Investors | 21,186,369 | $1.6B | 17.2% | — |
| 4 | BlackRock, Inc. | 10,442,476 | $784.1M | 8.5% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,808,902 | $586.4M | 6.3% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 7,118,330 | $534.5M | 5.8% | — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 6,391,816 | $480.0M | 5.2% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 5,857,629 | $439.8M | 4.8% | — |
| 9 | STATE STREET CORP | 3,995,564 | $300.0M | 3.2% | — |
| 10 | ROYAL BANK OF CANADA | 3,801,815 | $285.5M | 3.1% | — |
| 11 | Tweedy, Browne Co LLC | 2,275,625 | $170.9M | 1.8% | — |
| 12 | Artisan Partners Limited Partnership | 2,058,308 | $154.6M | 1.7% | ADD +74.2% |
| 13 | BAKER BROS. ADVISORS LP | 2,047,727 | $153.8M | 1.7% | — |
| 14 | GOLDMAN SACHS GROUP INC | 1,699,847 | $127.6M | 1.4% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,583,266 | $118.9M | 1.3% | — |
| 16 | FRANKLIN RESOURCES INC | 1,575,023 | $118.3M | 1.3% | — |
| 17 | Pictet Asset Management Holding SA | 1,434,995 | $107.1M | 1.2% | — |
| 18 | Invesco Ltd. | 1,277,358 | $95.9M | 1.0% | — |
| 19 | MORGAN STANLEY | 1,026,509 | $77.1M | 0.8% | — |
| 20 | VANGUARD FIDUCIARY TRUST CO | 1,024,377 | $76.9M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Artisan Partners Limited Partnership | ADD | 1,181,416 | 2,058,308 | +74.2% | $154.6M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | TRIM | 1,352,837 | 907,533 | -32.9% | $68.1M | 2026-Q1 |
| Polar Capital Holdings Plc | TRIM | 1,333,424 | 829,511 | -37.8% | $62.3M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 1,063,327 | 737,859 | -30.6% | $55.4M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 773,184 | 529,954 | -31.5% | $39.8M | 2026-Q1 |
| Neuberger Berman Group LLC | DOUBLED | 108,044 | 443,272 | +310.3% | $33.3M | 2026-Q1 |
| Capital Research Global Investors | NEW | — | 323,015 | — | $24.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 223,607 | 305,549 | +36.6% | $22.9M | 2026-Q1 |
| Hudson Bay Capital Management LP | TRIM | 475,000 | 295,100 | -37.9% | $22.2M | 2026-Q1 |
| ARK Investment Management LLC | TRIM | 422,968 | 288,716 | -31.7% | $21.7M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 176,035 | 267,215 | +51.8% | $20.1M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 83,875 | 227,084 | +170.7% | $17.1M | 2026-Q1 |
| Trexquant Investment LP | ADD | 132,241 | 213,645 | +61.6% | $16.0M | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 26,941 | 185,967 | +590.3% | $14.0M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 115,917 | 157,222 | +35.6% | $11.8M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | NEW | — | 142,201 | — | $10.7M | 2026-Q1 |
| NOMURA HOLDINGS INC | NEAR_EXIT | 848,815 | 114,080 | -86.6% | $8.6M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 80,729 | 108,744 | +34.7% | $8.2M | 2026-Q1 |
| Gotham Asset Management, LLC | DOUBLED | 43,212 | 98,968 | +129.0% | $7.4M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 256,933 | 95,954 | -62.7% | $7.2M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 43,912 | 62,919 | +43.3% | $4.7M | 2026-Q1 |
| Orion Porfolio Solutions, LLC | DOUBLED | 23,574 | 61,344 | +160.2% | $4.6M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 140,000 | 50,000 | -64.3% | $3.8M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 3,661 | 48,244 | +1217.8% | $3.6M | 2026-Q1 |
| BAMCO INC /NY/ | ADD | 36,000 | 45,000 | +25.0% | $3.4M | 2026-Q1 |
17 unique insiders with 50 transactions. Net insider value: -$29.9M ($0.00 bought, $29.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | HANTSON LUDWIG | Director | AWARD | 10,753 | — | — |
| Jun 4, 2026 | Reikes Peter N | Director | AWARD | 10,753 | — | — |
| Jun 1, 2026 | BERTHELSEN SPENCER R | Director | SELL | 8,000 | $75.67 | $605.4K |
| Jun 1, 2026 | BERTHELSEN SPENCER R | Director | EXERCISE | 8,000 | $24.42 | $195.4K |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | EXERCISE | 3,220 | $32.60 | $105.0K |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | SELL | 3,220 | $78.68 | $253.3K |
| May 13, 2026 | Monia Brett P | Chief Executive Officer | EXERCISE | 1,316 | $32.60 | $42.9K |
| May 13, 2026 | Monia Brett P | Chief Executive Officer | SELL | 1,316 | $78.01 | $102.7K |
| May 4, 2026 | LOSCALZO JOSEPH | Director | SELL | 59,508 | $74.90 | $4.5M |
| May 4, 2026 | LOSCALZO JOSEPH | Director | EXERCISE | 10,968 | $38.06 | $417.4K |
| May 1, 2026 | KLEIN JOSEPH III | Director | EXERCISE | 10,111 | $47.11 | $476.3K |
| May 1, 2026 | KLEIN JOSEPH III | Director | SELL | 8,680 | $73.35 | $636.7K |
| Apr 28, 2026 | Baroldi Joseph | EVP, Chief Business Officer | SELL | 1,626 | $71.79 | $116.7K |
| Apr 16, 2026 | Baroldi Joseph | EVP, Chief Business Officer | SELL | 5,619 | $74.56 | $419.0K |
| Apr 16, 2026 | Birchler Brian | EVP, Corp and Development Ops | SELL | 973 | $75.04 | $73.0K |
| Apr 16, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | SELL | 4,902 | $75.17 | $368.5K |
| Apr 15, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | EXERCISE | 12,226 | — | — |
| Apr 15, 2026 | Baroldi Joseph | EVP, Chief Business Officer | EXERCISE | 10,837 | — | — |
| Apr 15, 2026 | Birchler Brian | EVP, Corp and Development Ops | EXERCISE | 1,875 | — | — |
| Apr 15, 2026 | PARSHALL B LYNNE | Director | SELL | 4,466 | $76.19 | $340.3K |
| Apr 2, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | SELL | 6,193 | $74.05 | $458.6K |
| Apr 1, 2026 | KLEIN JOSEPH III | Director | EXERCISE | 12,000 | $38.06 | $456.7K |
| Apr 1, 2026 | KLEIN JOSEPH III | Director | SELL | 20,105 | $75.50 | $1.5M |
| Mar 19, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | SELL | 5,812 | $70.97 | $412.5K |
| Mar 17, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | SELL | 10,172 | $73.21 | $744.7K |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | EXERCISE | 33,118 | — | — |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | SELL | 205,608 | $72.38 | $14.9M |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | EXERCISE | 60,299 | $60.89 | $3.7M |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | EXERCISE | 4,675 | — | — |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | SELL | 21,191 | $75.50 | $1.6M |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | EXERCISE | 32,602 | $46.10 | $1.5M |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | EXERCISE | 34,103 | $60.89 | $2.1M |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | SELL | 16,512 | $75.47 | $1.2M |
| Mar 9, 2026 | Monia Brett P | Chief Executive Officer | SELL | 7,382 | $74.11 | $547.1K |
| Mar 9, 2026 | Monia Brett P | Chief Executive Officer | EXERCISE | 40,822 | $60.89 | $2.5M |
| Mar 9, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | SELL | 10,148 | $75.25 | $763.7K |
| Mar 4, 2026 | LOSCALZO JOSEPH | Director | EXERCISE | 200 | $38.06 | $7.6K |
| Mar 4, 2026 | Baroldi Joseph | EVP, Chief Business Officer | EXERCISE | 238 | $56.78 | $13.5K |
| Mar 4, 2026 | Baroldi Joseph | EVP, Chief Business Officer | EXERCISE | 201 | — | — |
| Mar 3, 2026 | Baroldi Joseph | EVP, Chief Business Officer | SELL | 4,096 | $79.36 | $325.1K |
| Mar 3, 2026 | LOSCALZO JOSEPH | Director | EXERCISE | 832 | $38.06 | $31.7K |
| Mar 3, 2026 | Diaz Allene M. | Director | EXERCISE | 10,321 | $41.08 | $424.0K |
| Mar 3, 2026 | Diaz Allene M. | Director | EXERCISE | 12,000 | — | — |
| Mar 3, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | EXERCISE | 16,463 | $32.60 | $536.7K |
| Mar 3, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | EXERCISE | 3,510 | $37.58 | $131.9K |
| Mar 3, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | EXERCISE | 6,951 | — | — |
| Mar 3, 2026 | Baroldi Joseph | EVP, Chief Business Officer | EXERCISE | 879 | — | — |
| Feb 27, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | J | 261 | $48.87 | $12.8K |
| Feb 27, 2026 | Swayze Eric | EVP Research | J | 256 | $48.87 | $12.5K |
| Feb 27, 2026 | Birchler Brian | EVP, Corp and Development Ops | J | 351 | $48.87 | $17.2K |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
3/10
Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for sev
Jun 12, 2026
NEUTRAL
8-K
3/10
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 20
Jun 8, 2026
BULLISH
8-K
7/10
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a
May 28, 2026
NEUTRAL
CLUSTER
3/10
Two IONS directors sold approximately $5.1M in stock, which is trivial relative to the company's $12
May 6, 2026
BULLISH
8-K
8/10
Ionis Pharmaceuticals announced positive results from the pivotal study of zilganersen in Alexander
Apr 21, 2026
NEUTRAL
CLUSTER
3/10
Two Ionis Pharmaceuticals executives, including the Chief Business Officer and EVP of Corporate and
Apr 17, 2026
MIXED
8-K
6/10
Ionis Pharmaceuticals reported full-year 2025 revenue of $944 million, exceeding guidance due to str
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 33 analysts: 10 strong buy, 17 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$102.17 mean target
+39.4% upside
Strong Buy (1.68)
$47.00 Low
$130.00 High
| Metric | Value |
|---|---|
| Current Price | $73.28 |
| Target Low | $47.00 |
| Target Mean | $102.17 |
| Target Median | $105.00 |
| Target High | $130.00 |
| # Analysts | 24 |
| Recommendation | Strong Buy (1.68) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.87 | $-1.03 | $-0.64 | -203.3% | +0.0% | 4↑ 2↓ | $0.2B | -58.0% | 7 |
| Next Q 2026-09-30 |
$-0.81 | $-0.93 | $-0.61 | -32.2% | +0.0% | 5↑ 0↓ | $0.2B | 29.8% | 7 |
| Current FY 2026-12-31 |
$-2.61 | $-2.79 | $-2.04 | -69.1% | -2.1% | 7↑ 0↓ | $0.9B | -5.7% | 8 |
| Next FY 2027-12-31 |
$-0.64 | $-2.21 | $0.26 | 75.7% | -2.4% | 4↑ 3↓ | $1.5B | 67.6% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.874 | |
| 7d ago | $-0.874 | |
| 30d ago | $-0.874 | |
| 60d ago | $-0.947 | +0.072 |
| 90d ago | $-0.927 | +0.052 |
13 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 30, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 21, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 17 | 6 | 0 | 0 | 82% | |
| May 1, 2026 | 9 | 16 | 6 | 0 | 0 | 81% | |
| Apr 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Mar 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Feb 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Jan 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Oct 26, 2026
fda_pdufa
PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indication: chronic hepatitis B (CHB). NDA accepted for Pr
Sep 22, 2026
fda_pdufa
PDUFA: IONS — zilganersen in Alexander disease — 2026-09-22
FDA target action date 2026-09-22 for IONS (IONIS PHARMACEUTICALS INC). Drug: zilganersen. Indication: Alexander disease. PDUFA action date set for zi
Jun 30, 2026
fda_pdufa
PDUFA: IONS — olezarsen in severe hypertriglyceridemia (sHTG) — 2026-06-30
FDA target action date 2026-06-30 for IONS (IONIS PHARMACEUTICALS INC). Drug: olezarsen. Indication: severe hypertriglyceridemia (sHTG). sNDA accepted
Jun 12, 2026
short_volume
Short Volume: IONS — 60.6% short (0.6M / 1.1M)
Short: 643,059 | Exempt: 0 | TRF Vol: 1,061,637 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: IONS — 72.6% short (0.7M / 1.0M)
Short: 725,647 | Exempt: 0 | TRF Vol: 999,257 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: IONS — 59.7% short (0.4M / 0.7M)
Short: 409,970 | Exempt: 941 | TRF Vol: 687,148 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: IONS — 57.0% short (0.3M / 0.6M)
Short: 316,982 | Exempt: 73 | TRF Vol: 556,432 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: IONS — 66.5% short (0.5M / 0.8M)
Short: 533,630 | Exempt: 31 | TRF Vol: 802,247 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: IONS — 63.0% short (0.3M / 0.5M)
Short: 318,576 | Exempt: 4,545 | TRF Vol: 505,974 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IONS — 76.6% short (0.6M / 0.7M)
Short: 563,932 | Exempt: 615 | TRF Vol: 735,804 | Short Ratio: 76.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: IONS — 58.1% short (0.4M / 0.6M)
Short: 362,241 | Exempt: 14 | TRF Vol: 623,981 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: IONS — 76.9% short (0.9M / 1.1M)
Short: 874,404 | Exempt: 1,202 | TRF Vol: 1,137,660 | Short Ratio: 76.9% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: IONS — 73.4% short (0.6M / 0.8M)
Short: 620,303 | Exempt: 940 | TRF Vol: 844,909 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: IONS — 56.6% short (0.3M / 0.6M)
Short: 320,655 | Exempt: 398 | TRF Vol: 566,292 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: IONS — 3.4M shares, 49,283 trades
Week starting 2026-05-18. Total ATS volume: 3,442,223 shares across 49,283 trades.
May 8, 2026
Clinical Trial
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
Phase Phase 2 — COMPLETED
Apr 23, 2026
Clinical Trial
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Phase Phase 2 — COMPLETED
Apr 2, 2026
Clinical Trial
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Phase Phase 3 — ACTIVE_NOT_RECRUITING